Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE ... while revenue for Zepbound surged from $175.8 million to $1.9 billion.

This surge was largely driven by its blockbuster GLP-1 receptor agonists, Mounjaro and Zepbound, which dominate the obesity and diabetes markets. Eli Lilly’s net income doubled compared to Q4 ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016 ...

But this could soon change. Zepbound is a prescription-only weight loss drug manufactured by Eli Lilly. People prescribed this medication inject themselves with weekly doses. According to the FDA ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate ...

Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a cancer drug from Scorpion Therapeutics Inc. The pharmaceutical company ...

Eli Lilly, the manufacturer of Mounjaro and Zepbound, did not immediately respond to a request for comment. While reports of vision problems in patients taking semaglutide and tirzepatide are rare ...